End-of-day quote
Other stock markets
|
||
- USD | - |
04-10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
03-15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
Chart calendar Sorrento Therapeutics Inc
Upcoming events on Sorrento Therapeutics Inc
No events available
Past events on Sorrento Therapeutics Inc
08/03/2023 | Q4 2022 Earnings Release (Projected) |
14/12/2022 | Annual General Meeting |
17/11/2022 16:30 | Investor Meeting - Key Opinion Leader |
12/11/2022 | American College of Rheumatology Convergence Conference |
09/11/2022 15:00 | Extraordinary Shareholders Meeting |
14/09/2022 13:00 | Morgan Stanley Global Healthcare Conference |
14/08/2022 | Interim 2022 Earnings Release |
05/05/2022 22:05 | American Society of Interventional Pain Physicians Meeting |
04/05/2022 | Q1 2022 Earnings Release |
27/04/2022 15:00 | B Riley Securities Virtual Neurology & Ophthalmology Conference |
22/04/2022 | Chinese Society of Clinical Oncology Guideline Conference |
06/01/2022 19:50 | Longwood Healthcare Leaders Winter Conference |
04/01/2022 22:00 | H.C. Wainwright BioConnect Virtual Conference |
01/12/2021 20:30 | Evercore ISI HealthCONx Conference |
15/11/2021 20:00 | Annual General Meeting |
29/09/2021 17:35 | Benzinga Healthcare Small Cap Conference - Panel |
29/09/2021 16:30 | Benzinga Healthcare Small Cap Conference |
29/09/2021 14:20 | Cantor Fitzgerald Global Healthcare Conference |
12/09/2021 | H.C. Wainwright Global Investment Conference |
05/08/2021 | Interim 2021 Earnings Release |
Annual results
Fiscal Period | December | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 21,2 17,8 19.22% | 31,4 25,2 24.74% | 40,0 41,3 -3.1% | 52,9 58,1 -8.91% | 62,8 65,9 -4.65% |
EBITDA Million USD | Released Forecast Spread | -117 -105 -10.86% | -180 -187 3.41% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - |
EBIT Million USD | Released Forecast Spread | -150 -139 -8.32% | -259 -236 -9.79% | -245 -214 -14.42% | -377 -368 -2.62% | -504 -448 -12.68% |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -214 -194 -10.1% | -360 -346 -3.78% | -311 -282 -10.22% | -463 -368 -25.79% | -562 -462 -21.59% |
Net income Million USD | Released Forecast Spread | -204 -183 -11.18% | -292 -235 -24.22% | -298 -282 -5.71% | -428 -367 -16.57% | -573 -419 -36.74% |
EPS USD | Released Forecast Spread | -1,92 -1,73 -10.77% | -2,20 -2,23 1.35% | -1,30 -1,23 -5.69% | -1,45 -1,25 -16% | -1,37 -1,01 -35.64% |
Announcement Date | 15/03/19 | 03/03/20 | 19/02/21 | 11/03/22 | 16/03/23 |
Quarterly results
Fiscal Period | December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 |
---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 13,5 17,0 -20.59% | 12,1 16,9 -28.63% | 13,1 18,3 -28.36% | 18,4 21,1 -12.96% | 11,5 29,4 -61.04% | 17,4 15,5 12.26% | 15,6 18,7 -16.43% | 16,3 20,0 -18.75% |
EBIT Million USD | Released Forecast Spread | -101 -72,1 -39.48% | -90,3 -87,8 -2.76% | -114 -80,8 -41.18% | -107 -78,7 -35.75% | -118 -71,6 -65.23% | -109 -102 -7.83% | -170 -113 -50.29% | |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -167 -70,1 -138.55% | -120 -85,7 -39.7% | -178 -83,3 -113.89% | -38,9 -76,3 48.98% | -221 -69,1 -219.08% | -91,7 -105 12.41% | -210 -111 -90.04% | |
Net income Million USD | Released Forecast Spread | -167 -70,1 -137.55% | -120 -85,7 -39.73% | -144 -83,3 -73.47% | -40,8 -76,3 46.53% | -219 -69,1 -216.42% | -89,6 -104 13.7% | -224 -69,8 -220.56% | |
EPS USD | Released Forecast Spread | -0,57 -0,24 -137.5% | -0,40 -0,29 -37.93% | -0,47 -0,27 -74.07% | -0,12 -0,22 45.45% | -0,54 -0,20 -170% | -0,20 -0,26 23.08% | -0,49 -0,15 -226.67% | -0,26 -0,16 -62.5% |
Announcement Date | 06/08/21 | 05/11/21 | 11/03/22 | 05/05/22 | 15/08/22 | 08/11/22 | 16/03/23 | 15/05/23 |
Past sector events for Sorrento Therapeutics Inc
- Stock Market
- Equities
- SRNE Stock
- Stock
- Calendar Sorrento Therapeutics Inc